Jim Cramer praises Eli Lilly for potential in weight loss drug market

From Yahoo Finance: 2025-05-07 10:24:00

Jim Cramer noted a shift in sentiment towards AI, stating it’s now seen as beneficial. He highlighted US-China tensions over AI, with the US restricting AI chip sales to China. Cramer criticized the US AI chip sanctions, calling them ‘Diffusion Rules’ that favor friendly nations. He expressed concerns about offering licenses to unfriendly countries.

Cramer discussed the impact of tariffs on economic growth, emphasizing the importance of the next quarter. He listed stocks mentioned on CNBC’s Squawk on the Street and the number of hedge fund investors. Cramer highlighted Eli Lilly and Company’s (LLY) potential, ranking it 8th in his list. He believes some AI stocks offer higher returns in a shorter time frame.

Eli Lilly and Company (LLY) is favored by Jim Cramer for its non-weight loss drug portfolio and manufacturing investments. Cramer sees potential in the weight loss drug market, particularly in pill form. LLY ranks 8th on Cramer’s stock list, but he suggests some AI stocks may offer greater returns within a shorter time frame. He recommends looking into an AI stock with substantial upside potential.



Read more at Yahoo Finance: Jim Cramer Says Eli Lilly and Company (LLY) CEO David Ricks Is ‘Very Conservative’